Vol. 6 No. 6 (2026): June
Reimbursement Reviews

Toripalimab (Loqtorzi)

decorative image of the issue cover

Published June 10, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses toripalimab 240 mg per 6 mL (40 mg per mL) sterile solution for IV infusion.
  • Indication: In combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or with recurrent, locally advanced NPC.